Daily intravenous or intraperitoneal injection of TGF-1 has been shown to protect animals from the occurrence of CIA. is an autoimmune disease with a worldwide incidence of approximately 0.51.0%, characterized by severe synovitis that results in articular destruction and affects activity of daily life[1]. Local immune response against collagen-rich joint components usually occurs in single articular, and eventually affects the majority of joints[2]. Once activated by inflammation, the synovial cells begin to form aggressive pannus which invade into cartilage and bone then develop the nonreciprocal damage[3]. Although the exact etiology of RA remains elusive, inflammatory cytokines, such as TNF-, IL-6, IL-1 and IL-17, and autoreactive immune cells, including macrophages, T cells and B cells, play important roles in the pathogenesis[4]. Efforts to discover new target therapies have achieved considerable success such as the TNF- inhibitors and B cell depleting therapies. However, current treatments do not provide joint repair and anti-inflammatory effect simultaneously in the synovium. Therefore, there is a necessity to develop a therapeutic strategy that could aim anti-inflammatory effect and subsequent joint repair. Mesenchymal stem cells (MSC) possess multipotent capacity[5]and exhibit immunoregulatory properties[6]. In particular, MSC have inherently several advantages: they can be easily isolated from various organs, can differentiate into various types of cells, e.g., osteoblasts, chondrocytes and adipocytes, and generate regulatory T cells (Treg) which are guardian cells for maintaining immune tolerance. Meanwhile, accumulating evidences proved that the defective Atipamezole number or function of Treg play a crucial role during RA progression[7],[8]. In fact, the use of MSC has been reported to be safe and efficacious in a variety of autoimmune diseases, such as graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE) and multiple sclerosis (MS)[9][11]. Therefore, the dual function of immune regulation and tissue repair prompted us Atipamezole to consider MSC as a new treatment tool for RA. Until now, there have been conflicting reports of using MSC in treatment of rheumatic animal models. Multiple systemic administration of 15106MSC/mice is essential to achieve therapeutic effect[12]. The results of RA patients treated with MSC also reported controversial results. One group reported intravenous (IV) injection of 1106MSC/kg into 4 RA patients, while no one achieved the DAS-28-defined remission during the follow-up period[13]. The other report observed benefits by administration of 68108cells through IV and/or intra-articular (IA) to 3 RA patients, but without long follow-up[14]. These previous treatments require large cell number, which is processed through numerous subcultures that could enhance the appearance of various cytogenetic abnormalities. Moreover,in vitroexpansion longer than several weeks is reported to attenuate therapeutic effect[15]with decreased tissue repair ability[16]. However, MSC are the minority in their Atipamezole source tissues (bone marrow, adipose tissue or umbilical cord). Therefore,in vitroexpansion is requisite and leads to the necessity for reducing cell number for MSC cell therapy. Atipamezole The route of delivery is another key to consider MSC as a therapeutic tool. MSC originating from bone marrow lose their homing ability after a few hoursin vitroculture[17]. Thus, even though one would hope the MSC to migrate to the target lesion after systemic injection such as IV or intraperitoneal (IP), it seems to be a difficult goal to achieve. Meanwhile, unlike other promising results in patients with GvHD or SLE, the relative unique and complex structure of the joints may be a challenge for MSC to migrate during arthritis. Thus, we considered direct delivery of MSC to the joint. However, Atipamezole previous studies reported the low efficacy of IA administration into arthritis model compared Pik3r1 to IP[18], and the localization of MSC after infusion is poorly known[19]. Thus, to establish MSC as a realistic treatment tool for RA, we have developed a new delivery method that would force the MSC to reside at the implanted site maintaining their dual function. For appropriate delivery of MSC into the inflamed lesion, we utilized the adhesive properties of MSC by using scaffold. In.
Daily intravenous or intraperitoneal injection of TGF-1 has been shown to protect animals from the occurrence of CIA